Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

In this educational workshop, Parexel regulatory experts, all former regulators, will provide a comprehensive view of anti-drug conjugates (ADCs) for the treatment of cancer - from non-clinical, CMC, and clinical perspectives. In this 90-minute educational session, we will explore how ADCs are developed and characterized in the non-clinical stage, the critical considerations, and challenges in manufacturing processes (CMC), and the exciting clinical developments shaping the landscape of cancer therapy. Join us as we delve into the multidimensional aspects of ADCs and their potential to revolutionize cancer treatment.

Speakers